RT Journal Article
SR Electronic
T1 Measuring Oxygen Access: lessons from health facility assessments in Nigeria
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.21.21255772
DO 10.1101/2021.04.21.21255772
A1 Hamish R Graham
A1 Omotayo E Olojede
A1 Ayobami A Bakare
A1 Agnese Iuliano
A1 Oyaniyi Olatunde
A1 Adamu Isah
A1 Adams Osebi
A1 Tahlil Ahmed
A1 Rochelle Ann Burgess
A1 Eric D McCollum
A1 Tim Colbourn
A1 Carina King
A1 Obioma C Uchendu
A1 Adegoke G Falade
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/04/21/2021.04.21.21255772.abstract
AB The COVID-19 pandemic has highlighted global oxygen system deficiencies and revealed gaps in how we understand and measure “oxygen access”. We present a case study on oxygen access from 58 health facilities in Lagos state, Nigeria. We found large differences in oxygen access between facilities (primary vs secondary, government vs private) and describe four key domains to consider when measuring oxygen access.Use 8/58 (14%) of facilities had a functional pulse oximeter for detecting hypoxaemia (low blood oxygen level) and guiding oxygen care. Oximeters were typically located in outpatient clinics (12/27, 44%), paediatric ward (6/27, 22%), or operating theatre (4/27, 15%), not suitable for children, and infrequently used.Availability 34/58 (59%) facilities had a functional source of oxygen available on the day of inspection, of which 31 (91%) facilities had it available in a single ward area, typically the operating theatre or maternity ward.Cost Oxygen was free to patients at primary health centres, when available, but expensive in hospitals and private facilities, with the median cost for 2 days oxygen 13000 ($36 USD) and 27500 ($77 USD) naira, respectively.Patient access No facilities were adequately equipped to meet minimum oxygen demands for patients. We were unable to determine the proportion of hypoxaemic patients who received oxygen therapy with available data.We highlight the importance of a multi-faceted approach to measuring oxygen access that assesses access at the point-of-care, and ideally at the patient-level. We propose standard metrics to report oxygen access and describe how these can be integrated into routine health information systems and existing health facility assessment tools.SUMMARY BOXOxygen access is poorly understood and the most commonly used metrics (e.g. presence of an oxygen source) do not correlate well with actual access to patients.Pulse oximetry use is a critical indicator for the quality of oxygen services and may be a reasonable reflection of oxygen coverage to patients with hypoxaemia.Oxygen, and pulse oximeter, availability must be assessed at the point-of-care in all major service delivery areas, as intra-facility oxygen distribution is highly inequitable.Minimum functional requirements for oxygen sources must be assessed, as many oxygen concentrators and cylinders may be present without being in working order.Competing Interest StatementHG, EDM, CK are advisors to the Lifebox Foundation on pulse oximetry. AAB, AGF, HG are board members for Oxygen for Life Initiative (OLI), a private non-profit that has provided services to the INSPIRING project. SA, TA, CC, and PV are employed by Save the Children UK who are part of the partnership funding the research. TFO, MM are employees of GSK, a multinational for-profit pharmaceutical company that produces pharmaceutical products for childhood pneumonia, including a SARS-CoV2 vaccine, and no direct financial interests in oxygen or pulse oximeter products.Funding StatementThis work was funded through the GlaxoSmithKline (GSK)-Save the Children Partnership (grant reference: 82603743). Employees of both GSK and Save the Children UK contributed to the design and oversight of the study as part of a co-design process. Any views or opinions presented are solely those of the author/publisher and do not necessarily represent those of Save the Children UK or GSK, unless otherwise specifically stated. Sponsor: University College London (UCL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has received ethical approval from the Research Ethics Committee at: University of Ibadan (REF UI/EC/19/0551), Lagos State (REF LS/PHCB/MS/1128/VOL.V1/005), and University College London (REF 3433/005).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data is available on request from the authors.